<DOC>
	<DOC>NCT02966145</DOC>
	<brief_summary>The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.</brief_summary>
	<brief_title>4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Aphasia</mesh_term>
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<mesh_term>Tauopathies</mesh_term>
	<mesh_term>Aphasia, Primary Progressive</mesh_term>
	<mesh_term>Pick Disease of the Brain</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<criteria>No known history of neurological disease, or meet criteria for one of the following: Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy (PSP); or Oligo or Variant Progressive Supranuclear Palsy (o/vPSP) Needs a reliable study partner who has frequent contact with the participant, who is available to provide information about the participant, and who can accompany the participant to research visits as needed Must be willing and able to undergo testing procedures, which include longitudinal followup visits Must be able to walk five steps with minimal assistance Significant neurological disease other than CBD, PSP, or a variant PSP syndrome. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments or metal objects in the eyes, skin, or body In the site investigator's opinion, inability to complete sufficient key study procedures, or some other equivalent assessment of impairment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CBD</keyword>
	<keyword>CBS</keyword>
	<keyword>CBGD</keyword>
	<keyword>PSP</keyword>
	<keyword>nfvPPA</keyword>
	<keyword>oPSP</keyword>
	<keyword>vPSP</keyword>
	<keyword>o/vPSP</keyword>
	<keyword>Corticobasal Degeneration</keyword>
	<keyword>Corticobasal Syndrome</keyword>
	<keyword>Cortocal-basal Ganglionic Degeneration</keyword>
	<keyword>Progressive Supranuclear Palsy</keyword>
	<keyword>Nonfluent Variant Primary Progressive Aphasia</keyword>
	<keyword>Oligosymptomatic Progressive Supranuclear Palsy</keyword>
	<keyword>Variant Progressive Supranuclear Palsy</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Neuroimaging</keyword>
	<keyword>MRI</keyword>
	<keyword>PET</keyword>
	<keyword>Tau</keyword>
	<keyword>Oculomotor</keyword>
	<keyword>Retinal Imaging</keyword>
</DOC>